Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. has reported a robust increase in its financial performance for the first half of 2024, with a 5.9% growth in revenue to RMB 3.07 billion and an impressive 201.4% surge in net profit to RMB 438.2 million compared to the same period last year. The earnings per share also saw a substantial rise to RMB 10.31 cents. Despite these strong results, the company has decided not to propose an interim dividend.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
